Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
ACTIVE_NOT_RECRUITING
Status
Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Metastatic Endometrial Endometrioid Adenocarcinoma
- Recurrent Endometrial Endometrioid Adenocarcinoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- DRUG: Ipatasertib
- PROCEDURE: Magnetic Resonance Imaging
- DRUG: Megestrol Acetate
Sponsor
National Cancer Institute (NCI)
Collaborators